XNAS · Healthcare · Biotechnology
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-14 | Q3 2026 | -0.36 | -0.34 | +5.56% | $1.5M | ✅ Beat | -9.99% | -20.57% | — |
| 2026-05-15 | Q2 2026 | -0.32 | -0.99 | -210.94% | $1.7M | ❌ Miss | -12.91% | +0.10% | -22.90% |
| 2026-02-13 |
| Q1 2026 |
| -0.30 |
| -0.38 |
| -26.67% |
| $3.9M |
| ❌ Miss |
| +3.05% |
| -7.34% |
| +15.08% |
| 2025-12-23 | Q4 2025 | -0.24 | -0.11 | +54.17% | $0 | ✅ Beat | — | — | — |
| 2025-08-12 | Q3 2025 | -0.21 | -0.80 | -280.95% | $0 | ❌ Miss | -3.08% | -5.38% | -7.69% |
| 2025-02-14 | Q1 2025 | -1.25 | -1.30 | -4.00% | $0 | ❌ Miss | -8.18% | -33.09% | -43.12% |
| 2024-12-27 | Q4 2024 | -2.00 | -1.72 | +14.00% | $0 | ✅ Beat | +6.25% | +8.15% | -17.93% |
| 2024-08-12 | Q3 2024 | -1.50 | -1.50 | +0.00% | $0 | ➖ Inline | -11.69% | -7.38% | -23.32% |
Showing last 8 quarters.